ClinicalTrials.gg
CompletedNCT06808815Updated Feb 5, 2025

A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis

A Phase 1 interventional study of DC-806 and Placebo in Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.
  • Registered 3 years 4 months after the study started (first participant enrolled Sep 2021, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
22nd of 36
104 · median 181
Started
2021
with 1 other
Phase 1
9 of 36
none open now
Registered
35th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 22nd largest by enrollment, is one of 2 that started in 2021, is one of 9 in phase 1, and was the 35th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts. Each participant will enroll in only one part. For each participant, Part 1 will last up to 14 weeks, Part 2 will last up to 12 weeks, Part 3 will last up to 11 weeks including screening and follow-up.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Subjects (Parts 1 and 2)

  • Men and women participants must be between 18-55 years inclusive, at the time of .
  • Female participants must either be of non- or if of childbearing potential, must not be pregnant, breast feeding or lactating and use a highly effective method during treatment and for 90 days following last administered dose. In addition, male partners of female subjects of childbearing potential must use highly effective contraception for 90 days following the last administered dose
  • Male participants who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after their last dose of IMP.
  • Participants must agree not to donate semen or ova/oocytes during the study and for 90 days after the last dose of IMP.
  • Participants must have a (BMI) ≥ 18 and ≤ 35 kg/m2.
  • Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead and clinical laboratory assessments at the time of screening, as judged by the Investigator or designee.

Participants with Psoriasis (Part 3)

  • Men and women Participants must be between 18-65 years inclusive, at the time of informed consent.
  • Participants must have a documented diagnosis of plaque psoriasis for ≥ 6 months prior to screening.
  • Physicians Global Assessment (PGA) of 2/3 i.e. mild or moderate plaque psoriasis at baseline.
  • Body Surface Area (BSA) ≥3% at baseline.
  • A minimum of 2 psoriatic lesions of at least 2 cm x 2 cm at baseline, with at least 1 plaque in a site suitable for .
  • Female participants must either be of non-childbearing potential or if of childbearing potential, must not be pregnant, breast feeding or lactating and use a highly effective birth control method during treatment and for 90 days following last administered dose. In addition, male partners of female subjects of childbearing potential must use highly effective contraception for 90 days following the last administered dose.
  • Male participants who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after their last dose of IMP.
  • Participants must have a body mass index (BMI) ≥ 18 and ≤ 36 kg/m2.

Exclusion criteria

Exclusion Criteria:

Healthy Subjects (Parts 1 and 2)

  • History or presence of any acute or chronic medical or psychiatric condition that could interfere with the subject's safety during the clinical study or expose the subject to undue risk as judged by the Investigator or designee.
  • After 10 minutes supine rest at the time of screening or prior to dosing on Day 1, any vital signs values outside the following ranges:

    • Systolic blood pressure \<90 or >150 mmHg, or
    • Diastolic blood pressure \<50 or >95 mmHg, or
    • Pulse \<40 or >90 bpm
  • Any clinically significant abnormalities in resting at the time of screening or pre-dose Day 1 including prolonged (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator or designee.
  • Clinically significant abnormalities in renal function:

    • \<60 mL/min
  • Clinically significant abnormalities in liver function:

    • >1.5 x
    • Aminotransferases >1.5 x ULN
    • ALP >1.5 x ULN
  • History of latent TB, active tuberculosis, or a positive QuantiFERON® TB Gold result at screening. Patients with an indeterminate QuantiFERON® TB Gold result at screening will be allowed one retest; if not negative on retesting, the subject will be excluded.
  • Females who are pregnant, breast feeding or plan to be pregnant during the study period or 90 days after.
  • Female subjects with a positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) at screening or within 24 h prior to the first administration of IMP.
  • Positive serum surface antigen (HBsAg), virus antibodies (HCV Ab) or (HIV) 1 and/or 2 antibodies at screening.
  • Part 2 Only: Presence of active suicidal ideation or positive suicide behaviour using the "Baseline/Screening" version of the Columbia Suicide Severity Rating Scale (C-SSRS) and with either of the following criteria:

    • History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with a history of a suicide attempt more than 5 years ago should be evaluated by a mental healthcare professional (eg, locally licensed psychiatrist, psychologist, or master's level therapist) before enrolling into the study.
    • Suicidal ideation in the past month prior to the Screening Visit as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Baseline/Screening" version of the C-SSRS.

Participants with Psoriasis (Part 3)

  • History or presence of any clinically relevant acute or chronic medical or psychiatric condition other than psoriasis that could interfere with the patient's safety during the clinical study or expose the patient to undue risk as judged by the Investigator or designee.
  • A diagnosis of non-plaque psoriasis.
  • Plaque psoriasis restricted to the scalp, palms, soles and face.
  • Pustular, erythrodermic, inverse, and guttate psoriasis
  • Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium)
  • Diagnosis of psoriatic arthritis, uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with psoriasis for which a subject requires current systemic (oral, SC, or IV) (including , , biologics) immunosuppressant medical treatment
  • Treatment with biologics within 5 half-lives (if known) or 6 months prior to dosing on Day 1, whichever is longer
  • Has received any systemic immunosuppressants (e.g. Methotrexate, cyclosporine, hydroxyurea, and tacrolimus) or anakinra within 4 weeks of the first administration of study medication.
  • Has received phototherapy or any systemic medications/treatments that could affect psoriasis or PGA evaluation (including, but not limited to, oral or injectable corticosteroids, retinoids, psoralens, sulfasalazine, hydroxyurea, apremilast, or fumaric acid derivatives) within 4 weeks of the first administration of study medication
  • Has used topical medications/treatments that could affect psoriasis or PGA evaluation (including, but not limited to, corticosteroids, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, picrolimus, and tacrolimus) within 2 weeks of the first administration of study medication.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Part 1: DC-806

    Single ascending dose of DC-806 administered orally.

    Drug: DC-806

  • Placebo comparator
    Part 1: Placebo

    Placebo administered orally.

    Other: Placebo

  • Experimental
    Part 2: DC-806

    Multiple ascending doses of DC-806 administered orally.

    Drug: DC-806

  • Placebo comparator
    Part 2: Placebo

    Placebo administered orally

    Other: Placebo

  • Experimental
    Part 3:DC-806

    DC-806 administered orally

    Drug: DC-806

  • Placebo comparator
    Part 3: Placebo

    Placebo administered orally

    Other: Placebo

Interventions

  • DrugDC-806

    administered orally.

    Also known as: S011806, LY4100504

  • OtherPlacebo

    administered orally.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug.

    A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module.

    Time frame: Baseline Up To 7 Weeks

  2. Part 2: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug.

    A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module.

    Time frame: Baseline Up To 7 Weeks

  3. Part 3: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug.

    A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module.

    Time frame: Baseline Up To 11 Weeks

Secondary outcomes

  1. Part 1, Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of DC-806.

    PK: Cmax of DC-806.

    Time frame: Pre-dose up-to 48 hours post-dose

  2. Part 1, PK: Area Under the Concentration Versus Time Curve (AUC) of DC-806.

    PK: AUC of DC-806.

    Time frame: Pre-dose up-to 48 hours post-dose

  3. Part 1, PK: Time to reach maximum observed (Tmax) of DC-806

    PK: Tmax of DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  4. Part 1, PK: First-order elimination half-life (T1/2) of DC-806

    PK: Half-life (T1/2) DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  5. Part 2, PK: Maximum Observed Concentration (Cmax) of DC-806

    PK: Cmax of DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  6. Part 2, PK: Area Under the Concentration Versus Time Curve (AUC) of DC-806

    PK: AUC of DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  7. Part 2, PK: Time to reach maximum observed (Tmax) of DC-806

    PK: Tmax of DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  8. Part 2, PK: First-order elimination half-life (T1/2) of DC-806

    PK: Half-life (T1/2) DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  9. Part 3, PK: Maximum Observed Concentration (Cmax) of DC-806

    PK: Cmax of DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

  10. Part 3, PK: Ctrough of DC-806

    pre-dose of DC-806

    Time frame: Pre-dose up-to 48 hours post-dose

07

Study locations

1 site
  • The Medicines Evaluation Unit (MEU) Ltd.
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2022, 11 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 5, 2025
StartActual
Sep 22, 2021
Primary completionActual
Aug 23, 2022
CompletionActual
Aug 23, 2022
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06808815
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Sep 22, 2021
Primary completion
Aug 23, 2022
Completion
Aug 23, 2022
Last update
Feb 5, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 W Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DC-806

Start the discussion